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Abstract
Background: Type 2 diabetes is rapidly growing as a proportion of the disease burden in Australia as
elsewhere. This study addresses the cost effectiveness of an integrated approach to assisting general
practitioners (GPs) with diabetes management. This approach uses a centralized database of clinical data
of an Australian Division of General Practice (a network of GPs) to co-ordinate care according to national
guidelines.
Methods: Long term outcomes for patients in the program were derived using clinical parameters after
5 years of program participation, and the United Kingdom Prospective Diabetes Study (UKPDS)
Outcomes Model, to project outcomes for 40 years from the time of diagnosis and from 5 years post-
diagnosis. Cost information was obtained from a range of sources. While program costs are directly
available, and costs of complications can be estimated from the UKPDS model, other costs are estimated
by comparing costs in the Division with average costs across the state or the nation. The outcome and
cost measures are used derive incremental cost-effectiveness ratios.
Results: The clinical data show that the program is effective in the short term, with improvement or no
statistical difference in most clinical measures over 5 years. Average HbA1c levels increased by less than
expected over the 5 year period. While the program is estimated to generate treatment cost savings,
overall net costs are positive. However, the program led to projected improvements in expected life years
and Quality Adjusted Life Expectancy (QALE), with incremental cost effectiveness ratios of $A8,106 per
life-year saved and $A9,730 per year of QALE gained.
Conclusions: The combination of an established model of diabetes progression and generally available
data has provided an opportunity to establish robust methods of testing the cost effectiveness of a
program for which a formal control group was not available. Based on this methodology, integrated health
care delivery provided by a network of GPs improved health outcomes of type 2 diabetics with acceptable
cost effectiveness, which suggests that similar outcomes may be obtained elsewhere.
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There has been a plethora of research on the nature of dia-
betes and the response of the disease to various treatment
regimes, which has led to a broad agreement on the nature
of appropriate care for people with diabetes [1,2]. This
agreement has led to the preparation of guidelines for the
management of diabetes in many countries including
Australia [3]. There is strong evidence that guidelines-
based care can improve patient outcomes [4] particularly
when supported by central computerized systems for
patient tracking and provision of feedback to physicians
[5].
While the cost-effectiveness of many diabetes treatments
has been assessed (e.g. [2,6,7]) there has been little assess-
ment of guideline implementation. Recent studies from
the Netherlands [8,9] found implementation of diabetes
guidelines to be cost effective, with the level of cost effec-
tiveness varying between different aspects of care. Other
studies have addressed particular components of guide-
lines [10-12], or the value of guidelines in diabetes pre-
vention [13]. Each adopts, to a greater or lesser degree, the
approach of using primary data to measure dissemination
and implementation effects, and models to estimate long
term treatment expenses and outcomes. This approach
has been recommended in a systematic review of the effec-
tiveness and efficiency of guideline implementation [14].
There are no published studies on the cost effectiveness of
guideline implementation in Australia, though one study
[15] assessed the costs of implementation of multi-disci-
plinary systematic care. Other Australian studies address
the cost impact of diabetes care in Indigenous Australian
communities [16] or draw on overseas results to model
the potential cost effectiveness of prevention programs
[17,18].
This study addresses the cost effectiveness of a program
designed to integrate diabetes care and to improve guide-
line implementation in an Australian Division of General
Practice. Divisions are regional networks of general prac-
tices which, among other things, provide a platform for
regional approaches to the management of type 2 diabetes
in primary health care through the implementation of
guidelines-based programs. The purpose of the study is to
examine whether a Division-based program, which co-
ordinates information and provision of care, improves
outcomes for diabetic patients and is cost effective.
There are currently 119 Divisions in Australia which vary
in their geographic coverage, location, population and
numbers of general practices. They have a range of roles
including: maintaining and improving the standards of
general practice in a region; coordinating care between
GPs and other service providers; improving communica-
tion between general practice, hospitals, medical special-
ists and community health services and; taking an active
role in the continuum of education from undergraduate
through to postgraduate vocational training in general
practice [19,20].
A recent report on the value of the Divisions network
found little objective evidence examining the effects of
Divisions [21]. The few studies that have been undertaken
rely on process measures rather than health outcome
measures to investigate the effectiveness of Divisions. This
study, using clinical measures and a simulation model, is
able to estimate outcome measures for the diabetes pro-
gram in one Division. While the results are specific to the
Division chosen, they provide an indication of the poten-
tial benefits of the use of this approach more widely across
the Divisions network, and also illustrate the potential for
applying this methodology more widely to assess existing
programs.
As the study is observational, data are drawn from a range
of sources to assess the overall costs and benefits. The per-
spective taken is of the health system as a whole, including
all costs on whomsoever they fall. This encompasses the
national tax-funded health insurance scheme which may
be considered statutory insurance, voluntary health insur-
ance, and patient out-of-pocket costs.
Method
The intervention
The Southern Highlands Division of General Practice
(SHDGP) in New South Wales (NSW) implemented a dia-
betes program in 1995. All GPs in the SHDGP participate
in the program. The GPs remain the case managers for
their patients, and the program facilitates case manage-
ment by provision of information and education to the
GPs and by direct service provision to patients referred by
the GPs. The Division funds and arranges diabetes educa-
tion programs, dietitian services and an exercise program,
and arranges access to podiatry services.
The core of the program is the centralized database of dia-
betic patients which is regularly updated with clinical
information from the general practices. This database,
which includes information on care provision as well as
clinical indicators such as HbA1c measures, is used to
send recall reminders to GPs, to provide regular audit
reports to GPs on their adherence to guidelines, and to
provide regular and ad hoc clinical alerts. In particular, the
Division identifies patients who may be at risk of develop-
ing complications, and reports on them to their GPs.
The centralized database has been adapted for the diabe-
tes program from a patient information database designed
to manage information on cardiac and diabetic patientsPage 2 of 11
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database where clinicians have failed to report the results
of consultations, or patients have failed to attend for con-
sultations or tests, the quality of data used is high. All
pathology data are provided electronically from the
pathology laboratories, and demographic and other clini-
cal data are provided directly by the GPs to the Division,
either paper-based or electronically. The analysis under-
taken in this study draws on information from this cen-
tralized database and a range of other sources as outlined
below.
The SHDGP is a rural division with the majority of the
population living in three small towns. Its catchment pop-
ulation at the 2001 Census was 48,400 with 16% aged
over 65 and 33% under 25. The population is above the
median for socio-economic status as measured by the
Socio-Economic Index for Australia (SEIFA) prepared by
the Australian Bureau of Statistics [23]. The Division has
50 GP members in 16 practices and a relatively low level
of GP services compared to the national average (3.7 GP
services per head of population compared with 4.7 for
Australia as a whole) [24].
Methods
A cost-effectiveness analysis of the Southern Highlands
Division Diabetes Program is undertaken using a deci-
sion-analytic approach. As with many recent studies
[13,6,25] a simulation model is used to predict longer
term patient outcomes and complications for patients in
the program. To our knowledge there is no diabetes simu-
lation model available based on Australian data. The
United Kingdom Prospective Diabetes Study (UKPDS)
Outcome Model [19,26] used in this study is based on ten
years data from the UKPDS. This model predicts the costs
and the outcomes for patients from their time of diagnosis
with type 2 diabetes until death. Simulations are based on
a probabilistic discrete-time illness-death model which
has been validated within the UKPDS populations. The
UKPDS model is designed to capture the association
between different types of complications at an individual
patient level[27]. It includes the major complications of
diabetes, but not other problems such as ulceration and
hyper/hypoglycemia [26].
Projections from the UKPDS outcomes model are deter-
mined by observed clinical measures (including HbA1c,
blood pressure, BMI and cholesterol measures) both at
diagnosis and where available over a post-diagnosis
period. The model was used in this study without modifi-
cation to simulate the progression of diabetes and its com-
plications from time of diagnosis to death, and from a
time point which is 5 years after initial participation in the
program to death. The model simulates the progression of
diabetes under "conventional treatment" within the
UKPDS study. "Conventional treatment" is prescribed in
the UKPDS as clinic attendance every three months and
dietary advice, aimed to maintain fasting plasma glucose
below 15 mmol/L without symptoms of hyperglycemia
[2]. Conventional treatment in Australian practice will be
much more varied. The implications of this potential dif-
ference are likely to be small, as the issue of interest is the
difference between projections from diagnosis and projec-
tions after 5 years in the program. Where the estimated
impact of the program on the costs of complications as
derived from the model can be compared with estimates
derived from other sources, results are of a similar order.
It is common practice for models to draw on data from
countries other than those which are the subject of their
study. The CORE model for example [28], used data from
the UKPDS, data from the Framingham Study and other
data sources in United States, data from Sweden and
information from the international DIGAMI trial.
A sample of patients enrolled in the program was selected
as outlined below and the average annual incremental
cost of managing them in the diabetes program estimated.
These costs encompassed both the direct costs of manag-
ing the program, and any incremental costs or savings
flowing from changes in care for program participants.
Four categories of costs were included: the cost of the
SHDGP diabetes program; the primary care costs costs
arising from adherence to the guidelines for management
of diabetes; the cost of pharmaceuticals; and the cost of
inpatient hospital services.
Differences in costs in three of these categories (primary
care services provided in compliance with guidelines,
pharmaceutical treatment, and hospital treatment) can-
not be directly measured from the Division database.
However, it is possible to estimate these costs by compar-
ing costs in the SHDGP with costs for NSW or for Australia
as a whole. Cost estimates for managing complications
from the UKPDS Outcomes Model are used to provide
estimates of the costs of hospital treatment for compari-
son with the direct estimates available from Australian
information.
In summary, data from SHDGP patients are used to esti-
mate program impacts on the life years and quality
adjusted life expectancy of these patients, and to estimate
the costs of diabetes caused complications. These cost esti-
mates contribute to the estimated impact of the program
on hospital costs, while the program impacts on life years
and QALE are used to estimate cost effectiveness.
To convert the estimated annual program costs and the
related costs and savings to a 40-year time horizon, the
average annual estimates are assumed to be the same eachPage 3 of 11
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streams are discounted at five per cent per annum.
Although the modelling incorporates both deaths and
increased costs per capita due to complications as patients
age, it does not address per capita cost changes for phar-
maceutical costs or costs of GP compliance with guide-
lines. If the single year overall treatment savings followed
the pattern of the costs of complications, the 40 year total
estimate would be only 5 per cent different to the value
estimated by assuming constant costs. The dominant fac-
tor in the overall costs is the direct cost of the program,
which will not increase with patient ageing except at the
margin (e.g. dietician costs), but will decline with the
deaths of program participants. Allowance for the effect of
these deaths on program costs reduces the long term costs
by substantially more than any plausible increase in treat-
ment cost effects, but a fixed value approach was taken to
ensure that results were conservative.
The five per cent discount rate follows the standards used
in Australia in assessing pharmaceuticals and medical
services for public funding [29,30]. This level of discount-
ing is consistent with German, Swiss and French discount-
ing rates [18], although for the United Kingdom rates of
3.5% are used [25] and rates of 1.5% for clinical outcomes
and 6% for costs are quoted [18], and for the Netherlands
3% is used [12]. In the sensitivity analyses, a rate of 0% is
tested, but as 5% is at the higher end of international dis-
counting rates no higher value is used.
The health outcomes for the selected patients are esti-
mated over a 40-year period from diagnosis, using the
model of the long-term sequelae of patients with type 2
diabetes in the UKPDS Outcomes model. The measures
used are the changes in years of life expectancy and in
QALE. The impact on utility of different diabetes related
complications used in the model to estimate QALE is
based on a study of a UKPDS participants in 1997 [31].
Patient sample
Using National Health Survey data [32], the number of
identified type 2 diabetics in the SHDGP in 2005 was
expected to be 1,525. Overall the program had contact
with around 85% of the expected total number of identi-
fied diabetics in the region in 2004, although for 220 of
the known patients there were no clinical data.
While there were 1,087 type 2 diabetic patients included
on the database at some time over the program, the
number included in the analysis was considerably less
than this as:
• The UKPDS model is designed to commence at time of
diagnosis, so patients who joined the program post diag-
nosis were excluded;
• Clinical advice suggested that patients should partici-
pate for around 5 years so that behavioural changes in
particular have stabilized (as the program had been run-
ning only 10 years, this requirement significantly reduced
the available sample);
• Data on all clinical items used in the model were
required at both diagnosis and after 5 years. Similar sys-
tems report only 50% to 60% of patients with an HbA1c
score recorded in any year [1], and in this study recording
of clinical results was similarly incomplete (to enhance
the sample size, if clinical data after 5 years were not avail-
able, data after 4 years or 6 years were accepted.
As a result of these exclusions, the final sample comprised
74 patients who registered at diagnosis and had complete
information both at diagnosis and approximately 5 years
after diagnosis.
As this group includes only five-year survivors, six addi-
tional patients who were randomly selected from among
those deceased within five years of joining the program
were added to the initial sample. Six patients were added
as eight per cent of the total patient group who registered
at or near diagnosis died during the following five years.
Gaps in the SHDGP data combined with the requirements
of the UKPDS model resulted in a sample which could
have introduced bias. However, as shown in Table 1, the
characteristics of all patients on enrolment were similar to
those of the study sample. Significant differences which
exist are in the expected directions. Table 1 also shows the
program has been effective in improving the status of the
sample over 5 years. Most clinical measures (e.g. choles-
terol) have improved or are stable, and the increase in
average HbA1c is less than would have been expected over
5 years under normal treatment [27].
Health outcomes
Life years and QALE were estimated over 40 years from
diagnosis using the UKPDS Outcome model. Outcomes
were first estimated from diagnosis with no constraint,
and secondly estimated with the constraints of actual clin-
ical measures after five years of program participation.
These two sets of projections gave estimates of life years
and QALE saved by program participants.
Southern Highlands Division of General Practice Diabetes 
Program costs
Division administrative costs, including the costs of
employing the program manager/diabetes educator, data
entry, general administration and IT costs, and the costs of
patient access to dietetic services and the exercise program
were provided by the Division. The details of these costs
are shown at Additional file 1.Page 4 of 11
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records and transfer of data to the Division, and the man-
agement of patient recall. These costs were estimated by
the Division based on consultation with the participating
practices and are also shown at Additional file 1.
Costs of compliance with guidelines
The cost of GP compliance with guidelines, and the flow
on costs to pathology testing, ophthalmology etc, were
based on data from the Service Incentives Payments (SIP)
scheme [33]. SIP payments are made to registered GPs on
completion of a 12 month cycle of guidelines based care
for a diabetic patient. Claims were made for 31% of
known diabetic patients in the SHDGP compared to 20%
across Australia as a whole [33]. These percentages were
combined with estimates of average national costs per
diabetic patient-year for out of hospital services [34]
(excluding pharmaceutical costs), and assumptions on
relative costs of compliant and non-compliant treatment,
to provide estimates of costs of guideline compliance (see
Additional file 1).
Pharmaceutical costs
A comparison of prescribing rates for oral antidiabetic
agents in the SHDGP with national rates, using publicly
available data from the Pharmaceutical Benefits Scheme
(PBS), was used to estimate differences in pharmaceutical
costs attributable to the program[35]. Details again are
shown in Additional file 1. As it is not possible to divide
insulin prescribing between type 1 and type 2 diabetic
patients, the cost of insulin has not been included. On the
other hand, these data do not include patient co-pay-
ments, which would lead to an under-estimate of any sav-
ings.
Costs of hospital services
Three estimates of cost savings were obtained for hospital
services. One estimate was based on the difference
between rates and costs of hospitalization for patients
with primary ICD-10 diagnosis codes 10–14 (diabetes)
residing in the Southern Highlands and in New South
Wales overall. These estimates were based on data pro-
vided by NSW Department of Health. As these are diabe-
tes-specific codes, they will not include all complications
of diabetes. The cost per patient-year for these two groups
($A255 and $A341 respectively) are well below the Aus-
tralian estimate of around $A600 per patient year [34] for
diabetes-related hospitalization. However, the actual hos-
pitalization data provide an indication of the level of sav-
ings in hospital costs for program participants.
The second estimate applied the percentage reduction in
the costs of treating complications attributed to the pro-
gram from the UKPDS model to an estimate of the average
Table 1: Comparison of characteristics of type 2 diabetes patients in the SHDGP Diabetes Program and patients included in the 
model(a)
Characteristics All patients at registration Patients included in the model
All 5 Year Survivors
At registration(c) At registration After 5 Years(d)
Gender (% female) 46.0 51.3 50.0 50.0
Average age at diagnosis (years) 59.2 62.3* 61.1 66.1
Average duration of diabetes (years) 4.1 0.1 0.1 5.1
Average HbA1c 7.4 6.9* 6.9 7.2
Average systolic blood pressure 135.9 135.1 135.1 132.9
Average lipid cholesterol level 5.4 6.1* 6.2 5.1**
Average HDL level cholesterol 1.3 1.2 1.2 1.3
Average BMI 31.1 31.7 31.9 32.0
% current smokers of those with known smoking(b) 15.0 20.0 21.6 21.6
Number of patients 1,372 80 74 74
Note: (a) There are different numbers of missing values for each characteristic for "All patients". There are 80 observations for all characteristics 
for patients included in the model.
(b) Smoking changes rarely reported.
(c) Asterisks show significantly different averages between the population and the group of 80 patients included in the modelling
▪ Age at diagnosis: as the patients in the model join the program at diagnosis they have lower average age at registration than the overall population 
of patients;
▪ Average HbA1c is higher for the population overall as they have a longer duration of diabetes
▪ Lipid cholesterol is lower for the population overall as they have been accessing lipid lowering drugs for longer.
(d) Double asterisk shows the significant differences between the patients included in the model at registration and 5 years later
▪ The only statistically significant difference is improved cholesterol, again almost certainly due to lipid lowering drugs.
Source: HDGP CarDiab databasePage 5 of 11
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in Australia [34]. The third approach used actual dollar
values of savings estimated by the UKPDS Outcomes
model. The three approaches provided estimates of a sim-
ilar order of magnitude, as shown at Additional file 1.
Results
Details of all costings are shown at Additional file 1. The
annual overall program cost per diabetic patient is esti-
mated to be $A196, including approximately $A100 of
direct Divisional costs, $A10 dietician costs, and $A6 costs
of an exercise program. The costs were calculated by aver-
aging total annual costs across 1,087 active type 2 diabetic
patients.
Costs to practices depend on whether electronic or paper
systems were used, and were estimated to be between
$A30 and $A80 per patient per year. The higher level of
practice costs is consistent with previous research [15],
which found ongoing average practice costs (in 2005
prices) were $A5,798 per practice compared with the aver-
age cost per practice in this study of $A6,535 (using the
$A80 per patient cost). Total program costs therefore
range from $A146 to $A196 per patient per year, with the
higher value used as the base estimate.
The estimated costs of additional compliance with diabe-
tes treatment guidelines for the SHDGP relative to the rest
of Australia are shown in detail in Additional file 1.
Depending on assumptions regarding the relative average
costs of guideline compliant and non-compliant treat-
ment, the estimated additional costs of compliance in the
SHDGP range from $10 to $90 per patient per year, with
a value of $A50 being used in the cost effectiveness calcu-
lations. This figure is consistent with the costs of compli-
ance being around twice the costs of non-compliance. If
patients following guidelines attended GPs four times per
year, and other patients attended annually, with testing
following similar ratios, an average cost ratio of four
would be possible. Many patients who do not fully com-
ply with guidelines, however, still attend a GP relatively
frequently (if only to obtain the relevant medicines). A
range from 1.25 to 4.00 in relative costs was therefore
used.
Estimated costs for treatment of complications over 40
years derived from the UKPDS model, together with 95%
confidence intervals, are shown in Table 2. In proportion-
ate terms, the program achieves an estimated 7.4% reduc-
tion in treatment costs for complications. Applying this
percentage to the average annual cost of hospitalization of
diabetic patients in Australia [34] gives an estimated sav-
ing of $44 per patient-year between the baseline and the
program group.
Table 2 also shows the absolute value of cost savings per
patient over 40 years to be £617, which is equivalent to
$A1,470 in 2005 prices, and to $A81.50 per patient-year
savings (assuming a constant cost over time). The use of
the proportionate reduction in costs applied to Australian
estimates of the annual costs of hospitalization is pre-
ferred as the cost structures and boundaries of "costs of
Table 2: Costs for diabetes-related complications and health outcomes from the UKPDS Outcomes Model using the Australian patient 
sample from the SHDGP Diabetes Program
Treatment cost(a)(b) Difference(b)
No program Program Absolute %
£8,325 £7,708 -£617 -7.4
(£7,076 – £9,574) (£6,444 – £8,972) (-£2,394 – +£1,160)
Health outcome(c) Difference(c)
No program Program Absolute %
Life-years 10.89 11.25 0.36 3.3
(10.52 – 11.26) (10.87 – 11.63) (-0.17 – +0.89)
QALE 8.25 8.54 0.30 3.6
(7.98 – 8.51) (8.27 – 8.81) (-0.08 – +0.68)
(a) Treatment cost for diabetes-related complications from the UKPDS model using clinical data from the Australian patient sample
(b) 95% confidence intervals in parentheses. Confidence interval for difference calculated as though independent estimates. These costs are health 
care costs associated with diabetes-related complications. They do not include ongoing care costs other than for complications. Costs reflect health 
care utilisation in the UK in the year 2000. Discount rate = 5% per annum
(c) 95% confidence intervals in parentheses. Confidence interval for difference calculated as though independent estimates. Discount rate = 5% per 
annum.
Source: SHDGP Diabetes Program; UKPDS Outcomes Model [26]Page 6 of 11
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tralia, while the proportionate effect of the program on
the costs of complications is likely to be same as the pro-
portionate effect on Australian hospital costs.
Comparing average hospital costs across the relevant ICD-
10 codes (codes 10–14) per known diabetic patient in
SHDGP with the average across New South Wales pro-
vided an estimated net saving of $86 per patient year, con-
sistent with the estimated savings derived from the
UKPDS Outcomes model. To be conservative, the figure
of $44 saving was used in the cost effectiveness calcula-
tions, while the higher $86 figure was used in the sensitiv-
ity analyses.
The average cost to the PBS per patient year of prescribing
of oral anti-diabetic drugs in the SHDGP is approximately
$40 less than the national figure. While the estimated $40
savings in prescribing is used to derive the estimated cost
effectiveness, a lower bound estimate of zero savings is
used in the sensitivity analyses.
Table 3 summarizes the estimated impact of the program
on hospitalization, antidiabetic prescribing, and guide-
line compliance, with an aggregate estimate of overall
treatment costs savings of $A34 per patient-year against
the cost of the diabetes program of $196 per patient year.
The net cost of the program is positive, even when the
most optimistic figures are taken for both treatment
effects and program costs. The overall net cost estimates
range from $30 per patient-year to $242 per patient-year
as shown in Table 4.
The health outcomes derived from the UKPDS Outcome
Model are shown in Table 2. The program is estimated to
achieve an increase in discounted life expectancy of 0.36
years and an increase in discounted QALE of 0.30 years.
While neither of these estimated differences is signifi-
cantly different from zero using 95% two sided tests (with
standard errors of the difference conservatively calcu-
lated), the probability that there is a zero or negative effect
is small for both measures (life years: p = 0.09; QALE: p =
0.06).
Table 4 presents the results of the cost-effectiveness analy-
sis. The net program cost per patient over 40 years (dis-
counted at five per cent) is estimated to be $A2,919. The
resulting cost-effectiveness ratios are $8,108 per life year
saved, and $9,730 per year increase in QALE.
The cost-effectiveness ratios resulting from this study are
within the generally acceptable limits applied to health
care interventions. The only publicly available assessment
of limits in Australia shows that drugs are unlikely to be
recommended for listing on the PBS if they cost over
$A76,000 per life year and unlikely to be rejected if they
cost less than $A42,000 per life year (1998–99 values)
[36]. A range of thresholds have been proposed or have
been implicitly used in other countries to evaluate the rea-
sonableness of costs per quality adjusted life year, and
almost all are over $A32,000 in 2005 prices [37].
Sensitivity analyses
Three aspects of this study are addressed in assessing the
robustness of this main conclusion. Firstly, the five per
cent discount rate, while the Australian standard, is at the
high end of international standards. Secondly the effect
on the conclusion of the range of estimates from the dif-
ferent cost components is tested. Finally, the potential var-
iability in the gain in life years or QALE is considered.
Table 3: Treatment cost savings from SHDGP Diabetes Program (AUD 2005)
Cost saving per patient-year(a) Range for sensitivity testing
Hospitalization costs(b) -44 -86 to -44
Antidiabetic prescribing(c) -40 -40 to 0
Guideline compliance(d) +50 +10 to +90
Total -34 -116 to +46
(a) Negative sign indicates cost saving
(b) AIHW estimate health expenditure on diabetes per patient-year of $A1,469, with 37% for hospital services. Updating to 2005 prices gives an 
estimated expenditure of $A601 per patient-year on hospital services. Estimated savings are obtained by applying the percentage reduction in costs 
of treating complications from the UKPDS model (7.4% – see Table 2). The larger saving of $A86 per patient-year used in sensitivity testing is the 
difference between the cost of hospital episodes with ICD-10 codes 10–14 for SHDGP ($A255 per patient-year) and for NSW ($A341). Data 
provided by NSW Health.
(c) The difference between the annual cost to the PBS of prescription antidiabetic agents per type 2 diabetic patient in SHDGP ($A80.95) and 
nationally ($A121.50). Reflects a difference in the prescribing rate of 5.1 scripts per person in SHDGP and 7.7 nationally.
(d) The increase in treatment cost due to guideline compliance of $A50 is an indicative figure based on the average annual cost per diabetic patient 
of out-of-hospital medical services and other professional services of $A454 in 2005 prices and the difference between the proportion of known 
diabetic patients giving rise to SIP claims in SHDGP (31%) and nationally (20%).
Source: SHDGP Diabetes Program; [34], p.1 and Table 2; [33,35]Page 7 of 11
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improvement in expected life years and QALE from pro-
gram participation increases (from 3.3 per cent to 3.6 per
cent, and from 3.6 per cent to 4.5 per cent respectively),
and the percentage savings diminish (from 7.4 per cent to
6.3 per cent). Recalculating Table 4 with no discounting,
the estimated cost per QALE rises from $9,730 to $11,172,
with a similar increase in the cost per life year. These esti-
mates remain well within the range of acceptable costs.
As shown in Table 4, the estimated costs per life year or
per QALE using the maximum values of all cost compo-
nents, are $12,111 and $14,533 respectively. While
approximately 50 per cent above the base case, these fig-
ures also remain well within acceptable bounds.
Finally, the estimated improvements in health outcomes
are also subject to estimation error. This variability can be
displayed by use of cost effectiveness acceptability curves
(see for example [25,38]). Please see Figure 1 for charts 1
and 2 below show the probability that the cost per year of
life expectancy gained, or the cost per year of quality
adjusted life expectancy gained, is below any given value
of a ceiling ratio (a willingness to pay). Minimum and
maximum costs are shown as well as the best estimate. As
all cost estimates are positive, a decision maker who was
only prepared to accept this program with zero net cost
would not accept it, so the curves all show zero probabil-
ity of acceptance at zero willingness to pay.
However, the curves show that if a figure of $A42,000 [36]
is used as the acceptable limit (although it was seven years
old at the time of the study), using the base costing there
is a better than 85 per cent chance that the incremental
cost effectiveness ratio is less than this limit for both life
years saved and increased QALE.
Using the maximum estimated cost of the program there
is a better than 80 per cent chance the ratio is less than
$42,000. Even if the upper limit of the total net costs is
doubled, the probabilities of the program being within
the $42,000 willingness-to-pay limit are 71% and 68% for
life years and QALE respectively. The conclusions are
therefore very robust to both the variation of the esti-
mated outcomes and the known limitations in the costing
methods.
Discussion
Despite the estimated improvement in health outcomes
and reduced hospital costs, the study estimates an increase
in the overall net costs from the program. This is consist-
ent with other programs which improve diabetes out-
comes[25,8,9]. While outcomes can be improved at
relatively low cost, few of the approaches reduce costs
overall.
It has proved necessary to draw on a wide range of data to
estimate the cost impact of the SHDGP diabetes program.
While there are limitations in the methods and the data,
the use of a range of cost estimates provides considerable
robustness to the overall conclusion to be drawn regard-
ing the cost effectiveness of the program.
With any program addressing long term chronic diseases
like diabetes, it is necessary to use modelling approaches
to estimate long term outcomes and costs [14]. As long
term Australian data are not available, the use of a model
based on other data was inevitable. This follows the same
logic as other studies [28] which draw on many sources
for their model components.
Some costs and savings are estimated by comparing costs
in the SHDGP with those in the state of NSW, or in Aus-
tralia as a whole. These estimates could be biased as the
SHDGP is not the only division to implement a diabetes
program. However, a 2002 survey covering 80 per cent of
divisions with a diabetes program [39] found only
approximately 25,000 of the (self reported) 554,000 dia-
betic patients in 2001 [40] were covered by electronic reg-
ister recall systems. Given this low coverage, it is unlikely
Table 4: Results of cost effectiveness analysis for the SHDGP Diabetes Program(a)
Base case Lower bound Upper bound
Cost of SHDGP Diabetes Program per patient-year (Additional file 1) $196 $146 $196
Treatment cost savings per patient-year (Table 3) -$34 -$116 +$46
Net cost per patient-year $162 $30 $242
Discounted net cost per patient over 40 years(b) $2,919 $540 $4,360
Life-years saved (Table 2) 0.36 0.36 0.36
Increase in QALE (Table 2) 0.30 0.30 0.30
Cost per life-year saved $8,108 $1,502 $12,111
Cost per year increase in QALE $9,730 $1,802 $14,533
Note: (a) All dollar values are expressed in Australian dollars, 2005 prices.
(b) Assumes net cost per patient-year is the same each year for 40 years. Discount rate = 5% per annum.
Source: SHDGP Diabetes Program; UKPDS Outcomes Model [26]; [34], p.1 and Table 1; [33,35]Page 8 of 11
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Cost effectiveness acceptability curvesFigure 1
Cost effectiveness acceptability curves
Chart 1: Cost effectiveness acceptability curves based on life expectancy  
0.000
0.100
0.200
0.300
0.400
0.500
0.600
0.700
0.800
0.900
1.000
5 10 15 20 25 30 35 40 45 50
Value of ceiling ratio (A$000,2005)
Pr
o
ba
bi
ity
 c
os
t e
ffe
ct
iv
e
Min cost Base cost Max cost Double max cost
 
 
 
Chart 2: Cost Effectiveness acceptability curves base on QALE 
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BMC Health Services Research 2008, 8:205 http://www.biomedcentral.com/1472-6963/8/205that the other programs significantly influenced the com-
parative cost estimates in this study.
Policy-makers need to know whether to continue to sup-
port and fund organizationally based programs which
attempt to integrate care and encourage use of guidelines,
but have been put in place without formal control groups.
The approach taken here provides a methodology which
gives robust answers to questions regarding cost effective-
ness, after accommodating the limitations in the data.
The SHDGP diabetes program would appear to have
made a cost effective contribution to the wellbeing of the
diabetes patient in the SHDGP (although with positive
net cost), and as such provides a potential model to be
considered in other Divisions. A number of initiatives
introduced for GPs in Australia in recent times, like the
SHDGP diabetes program, have had as their objective the
improvement of care coordination and achievement of
more integrated care (for example the inclusion of items
in the Australian Medicare Benefits Schedule which pro-
vide incentives for GPs to take part in multi-disciplinary
care planning, and the incentive payments for GPs who
follow guidelines in care of diabetes and asthma). In this
respect, the US and Australian health care systems may be
heading towards a common end point in the longer term
(i.e. integrated care) although arriving at that end point by
different routes.
Conclusion
This study faces the problems inherent in attempting to
assess an existing program, with limits to direct data col-
lection and no formal control group. It has been shown,
however, that reasonable and robust estimates of cost
effectiveness of the diabetes management program can be
derived using clinical data from a central database and
cost data taken from a range of sources. The results show
that a program using a centralized computer-based regis-
ter, and providing some centralized services, is highly
likely to be cost effective although at a positive net cost.
This does not suggest that all programs undertaken by all
Divisions will be cost-effective. It does however demon-
strate both that it is possible to draw robust conclusions
about such programs if the net for data collection is cast
suitably wide, and that integrated care for diabetic
patients through enhanced GP networks can provide
value for money.
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